Search results
Showing 1486 to 1500 of 2105 results for technology appraisal
Nivolumab monotherapy for non-small-cell lung cancer [ID1088]
Discontinued Reference number: GID-TA10148
Discontinued Reference number: GID-TA10616
Discontinued Reference number: GID-TA10841
Pemetrexed for the first-line treatment of non-small-cell lung cancer (TA181)
Evidence-based recommendations on pemetrexed for untreated non-small-cell lung cancer in adults.
Evidence-based recommendations on 12 standard quality house dust mite sublingual lyophilisate (SQ-HDM SLIT; Acarizax) for treating allergic rhinitis and allergic asthma caused by house dust mites.
Discontinued Reference number: GID-TA10185
This guidance has been updated and replaced by NICE technology appraisal guidance 933. People already having tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies through the Cancer Drugs Fund can continue. For those people, it will be funded by the company until they and their NHS clinician consider it appropriate to stop.
Benralizumab for previously treated severe nasal polyps [ID1659]
Discontinued Reference number: GID-TA10818
Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [TSID12099]
In development Reference number: GID-TA11640 Expected publication date: TBC
Our guidelines make evidence based, best practice recommendations. These help to improve patient safety and reduce the risk of harm across the health system.
Health Technology Evaluation Develops guidance on the use of new and existing treatments within the NHS, such as medicines, medical...
Evidence-based recommendations on pembrolizumab (Keytruda) with chemotherapy before surgery (neoadjuvant) and then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults
Evidence-based recommendations on the CoaguChek XS system for self-monitoring coagulation status in adults and children. The recommendations originally included the InRatio2 PT/INR, but this was withdrawn from the market in October 2016 and is not currently available.
CareLink network service for remote monitoring of people with cardiac devices (MIB64)
NICE has developed a medtech innovation briefing (MIB) on the CareLink network service for remote monitoring of people with cardiac devices
This guideline covers care and management for adults (aged 18 and over) with type 2 diabetes. It focuses on education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.